Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML

Exclusion Criteria

• •1. Prior allogeneic bone marrow transplant if the patient still has active acute or chronic graft versus host disease requiring \>10 mg prednisone or equivalent corticosteroids.
• •2. Concomitant malignancies except carcinoma in situ, basal or squamous cell skin carcinoma. Patients who had no evidence of disease from another primary cancer for 2 or more years are allowed to participate in the trial. Localized non-metastatic prostate cancer, not requiring systemic treatment, and for which no local treatment is planned, is allowed.
• •3. Uncontrolled or severe intercurrent medical condition.
• •4. Previous treatment with an aminobisphonsphonate IV (e.g. ibandronate, pamidronate, zoledronate) within 4 weeks prior to initial IMP administration.
• •5. Known ongoing drug or alcohol abuse in the opinion of the investigator.
• •6. Previous autologous haematopoietic stem cell transplantation (HSCT) or treatment with Chimeric Antigen Receptor (CAR) T-cell therapy within 6 months prior to initial IMP administration.
• •7. Immunodeficiency disorders.
• •8. Patients with Richter's transformation are excluded.
• •Other eligibility criteria will apply during full screening.